Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
Ernexa Therapeutics (Nasdaq: ERNA) announced it will present new preclinical data for its lead cell therapy candidate ERNA-101 at the AACR Special Conference in Cancer Research on September 20, 2025. The presentation will focus on ERNA-101's ability to reprogram the ovarian tumor microenvironment.
The oral presentation, led by Dr. Michael Andreeff from MD Anderson Cancer Center, will showcase how ERNA-101, an off-the-shelf cell therapy using engineered induced pluripotent stem cells (iPSCs), can potentially activate the immune system to target cancer cells. The therapy demonstrates promise in restoring immune activity in difficult-to-treat ovarian tumors.
Ernexa Therapeutics (Nasdaq: ERNA) ha annunciato che presenterà nuovi dati preclinici sul suo candidato di terapia cellulare principale, ERNA-101, alla AACR Special Conference on Cancer Research il 20 settembre 2025. La presentazione si focalizzerà sulla capacità di ERNA-101 di riprogrammare il microambiente tumorale ovarico.
La presentazione orale, guidata dal Dott. Michael Andreeff del MD Anderson Cancer Center, mostrerà come ERNA-101, una terapia cellulare pronta all’uso che utilizza cellule staminali pluripotenti indotte ingegnerizzate (iPSC), possa potenzialmente attivare il sistema immunitario per mirare alle cellule tumorali. La terapia mostra potenziale nel ripristinare l’attività immunitaria in tumori ovarici difficili da trattare.
Ernexa Therapeutics (Nasdaq: ERNA) anunció que presentará nuevos datos preclínicos de su candidato líder de terapia celular, ERNA-101, en la Conferencia Especial AACR sobre Investigación del Cáncer el 20 de septiembre de 2025. La presentación se centrará en la capacidad de ERNA-101 para reprogramar el microambiente tumoral ovárico.
La presentación oral, a cargo del Dr. Michael Andreeff del MD Anderson Cancer Center, mostrará cómo ERNA-101, una terapia celular lista para usar que emplea células madre pluripotentes inducidas (iPSCs) diseñadas, puede potencialmente activar el sistema inmunológico para atacar las células cancerosas. La terapia demuestra potencial para restaurar la actividad inmunitaria en tumores ováricos de difícil tratamiento.
Ernexa Therapeutics (Nasdaq: ERNA)는 주력 세포 치료제 후보인 ERNA-101에 대한 새로운 전임상 데이터를 2025년 9월 20일 AACR 암 연구 특별 회의에서 발표할 예정이라고 발표했습니다. 발표는 ERNA-101의 난소 종양 미세환경 재구성 능력에 초점을 맞출 것입니다.
MD 앤더슨 암 센터의 Dr. Michael Andreeff가 이끄는 구두 발표는 엔지니어링된 유도 다능성 줄기세포(iPSCs)를 사용한 즉시 사용 가능한 세포 치료제인 ERNA-101이 면역 체계를 활성화해 암세포를 표적으로 삼을 수 있는 가능성을 보여줄 것이라고 할 것입니다. 이 치료법은 난소 종양의 면역 활성 회복에 잠재력이 있다고 평가됩니다.
Ernexa Therapeutics (Nasdaq: ERNA) a annoncé qu’elle présentera de nouveaux données précliniques sur son candidat phare de thérapie cellulaire, ERNA-101, lors de la AACR Special Conference sur la recherche sur le cancer, le 20 septembre 2025. La présentation portera sur la capacité d’ERNA-101 à reprogrammer le microenvironnement tumoral ovarien.
La présentation orale, dirigée par le Dr. Michael Andreeff du MD Anderson Cancer Center, démontrera comment ERNA-101, une thérapie cellulaire prête à l’emploi utilisant des cellules souches pluripotentes induites (iPSCs) conçues, peut potentiellement activer le système immunitaire pour cibler les cellules cancéreuses. La thérapie montre un potentiel pour restaurer l’activité immunitaire dans les tumeurs ovariennes difficiles à traiter.
Ernexa Therapeutics (Nasdaq: ERNA) gab bekannt, dass neue präklinische Daten zu ihrem führenden Zelltherapie-Kandidaten ERNA-101 bei der AACR Special Conference on Cancer Research am 20. September 2025 präsentiert werden. Die Präsentation konzentriert sich auf die Fähigkeit von ERNA-101, das Tumormikromilieu ovarian zu reprogrammen.
Die mündliche Präsentation unter der Leitung von Dr. Michael Andreeff vom MD Anderson Cancer Center wird zeigen, wie ERNA-101, eine einsatzbereite Zelltherapie, die engineered induced pluripotent stem cells (iPSCs) verwendet, das Immunsystem potenziell aktivieren kann, um Krebszellen anzugreifen. Die Therapie zeigt vielversprechende Ansätze, die Immunaktivität in schwer behandelbaren ovarian Tumoren wiederherzustellen.
Ernexa Therapeutics (ناسداك: ERNA) أعلنت أنها ستعرض بيانات جديدة قبل السريرية عن مرشحها الرئيسي للعلاج بالخلايا ERNA-101 في المؤتمر الخاص AACR عن أبحاث السرطان في 20 سبتمبر 2025. ستركز العرض على قدرة ERNA-101 على إعادة برمجة بيئة الورم الخبيث في المبيض.
سيُقدَّم العرض الشفوي، بقيادة الدكتور ميخائيل أندرييف من مركز MD Anderson للسرطان، ليبيّن كيف يمكن لـ ERNA-101، وهو علاج خلوي جاهز للاستخدام باستخدام الخلايا الجذعية المبرمجة المحفّرة (iPSCs)، أن يفعّل الجهاز المناعي لاستهداف الخلايا السرطانية. تُظهر هذه العلاج إمكانية استعادة النشاط المناعي في أورام المبيض التي يصعب علاجها.
Ernexa Therapeutics (纳斯达克代码：ERNA) 宣布将于 2025年9月20日 在 AACR 癌症研究特别会议上发布其领先细胞治疗候选药物 ERNA-101 的最新前临床数据。此次报告将重点介绍 ERNA-101 调整卵巢肿瘤微环境的能力。
本次口头报告由来自 MD Anderson 癌症中心的 Dr. Michael Andreeff 主持，将展示 ERNA-101（使用工程化的诱导多能干细胞 iPSCs 的现货细胞治疗）如何可能激活免疫系统以靶向癌细胞。这种治疗在重难治性卵巢肿瘤中显示出恢复免疫活性的潜力。
- None.
- None.
Presentation to highlight preclinical data from the company’s lead cell therapy, ERNA-101, demonstrating potential to reprogram the ovarian tumor microenvironment and advance toward clinical trials
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced preclinical data will be presented at the inaugural AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research. The oral presentation, taking place on September 20, 2025 in Denver, is titled “Gene-modified iPS-derived MSC restore a ‘Hot’ immune microenvironment in high-grade serous ovarian cancer.”
The presentation will highlight new preclinical findings from Ernexa’s lead program, ERNA-101, a synthetic, off-the-shelf cell therapy designed to activate and regulate the immune system to recognize and attack cancer cells. These findings support the continued advancement of ERNA-101 toward clinical evaluation in ovarian cancer. The oral presentation will be made by Michael Andreeff, M.D., Ph.D., professor at The University of Texas MD Anderson Cancer Center.
“This research underscores the promise of engineered iPSC-derived MSCs to fundamentally reshape the tumor microenvironment in ovarian cancer,” said Dr. Andreeff, the trial’s lead investigator. “By restoring immune activity in these difficult-to-treat tumors, ERNA-101 has the potential to open new therapeutic avenues where current options remain limited.”
Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) – a type of stem cell that can be reprogrammed from adult cells to become nearly any cell type in the body – and transforming them into induced mesenchymal stem cells (iMSCs). iMSC is a more specialized type of stem cell that has a unique ability to migrate toward tumors.
“This opportunity to share our ERNA-101 data on an international stage is an important milestone for Ernexa, and we are honored to partner with Dr. Andreeff, a leading pioneer in cell therapy, and specifically in MSCs,” said Sanjeev Luther, President and CEO of Ernexa Therapeutics. “AACR is a premier organization for scientific exchange, and we are proud to demonstrate the potential of our engineered cell therapies to expand treatment options for patients with ovarian cancer and beyond.”
Details of the oral presentation include:
- Session: Spotlight on Proffered Talks
- Title: Gene-modified iPS-derived MSC restore a ‘Hot’ immune microenvironment in high-grade serous ovarian cancer
- Date: Saturday, September 20 at 10:10 a.m.
- Location: Colorado Ballroom, Grand Hyatt Denver Hotel
Ernexa is also slated to deliver a poster presentation on the same topic.
Ernexa’s recent update on operational excellence enables the company to allocate valuable resources where they are needed most: advancing ERNA-101 into clinical trials. The data that Dr. Andreeff is presenting is critical, as ERNA-101 continues to receive strong validation in studies leading up to clinical trials.
About Ernexa Therapeutics
Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.
ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.
For more information, visit www.ernexatx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.
Media & Investor Relations Contact
FAQ
When is Ernexa Therapeutics (ERNA) presenting at the AACR Special Conference?
What is ERNA-101 and how does it work?
Who will be presenting Ernexa's (ERNA) research at the AACR conference?
What type of data will Ernexa (ERNA) present at the AACR conference?
What is the current development stage of ERNA-101?
